Last reviewed · How we verify
extended postimplantation dual antiplatelet therapy
Extended dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) prevents stent thrombosis and reduces cardiovascular events by inhibiting platelet aggregation for a prolonged period after coronary stent implantation.
Extended dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) prevents stent thrombosis and reduces cardiovascular events by inhibiting platelet aggregation for a prolonged period after coronary stent implantation. Used for Prevention of stent thrombosis and recurrent ischemic events after percutaneous coronary intervention with stent implantation in high-risk patients.
At a glance
| Generic name | extended postimplantation dual antiplatelet therapy |
|---|---|
| Sponsor | National Institute of Cardiology, Warsaw, Poland |
| Drug class | Antiplatelet therapy combination |
| Target | Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dual antiplatelet therapy (DAPT) combines two agents that work synergistically to prevent blood clots: aspirin irreversibly inhibits cyclooxygenase and thromboxane A2 production, while P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) block adenosine diphosphate-mediated platelet activation. Extended DAPT beyond the standard 12 months aims to reduce late stent thrombosis and recurrent ischemic events in high-risk patients, though it increases bleeding risk.
Approved indications
- Prevention of stent thrombosis and recurrent ischemic events after percutaneous coronary intervention with stent implantation in high-risk patients
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients (PHASE4)
- Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: